Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation
Adenocarcinoma-to-squamous cell carcinoma transformation (AST) induces drug resistance in patients with lung adenocarcinoma (LUAD), often resulting in unfavorable clinical outcomes. In recent years, it has been found that alterations in the tumor immune microenvironment (TIME) during adenosquamous c...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542526/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849724339927121920 |
|---|---|
| author | Haiyan Xu Ying Yang PingLi Wang Shengnan Lin Xiaochun Zhang Huiwen Ni Zhiyong Xu Zhiyong Xu |
| author_facet | Haiyan Xu Ying Yang PingLi Wang Shengnan Lin Xiaochun Zhang Huiwen Ni Zhiyong Xu Zhiyong Xu |
| author_sort | Haiyan Xu |
| collection | DOAJ |
| description | Adenocarcinoma-to-squamous cell carcinoma transformation (AST) induces drug resistance in patients with lung adenocarcinoma (LUAD), often resulting in unfavorable clinical outcomes. In recent years, it has been found that alterations in the tumor immune microenvironment (TIME) during adenosquamous carcinoma trans-differentiation also influence the efficacy of immunotherapy. Moreover, the aberrant expression and activation of several driver genes for AST lead to abnormal infiltration and function of immune cell by remodeling the cellular inflammatory phenotype. In this review, we will systematically present the changes in the TIME and molecular regulatory mechanisms during adenosquamous carcinoma differentiation, aiming to gain a better understand of the function of immune cells during this process and the potential value of combining immunotherapy to enhance the treatment of non-small cell lung cancer (NSCLC). |
| format | Article |
| id | doaj-art-666db45be0c94e71b3b4d7e8be73682d |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-666db45be0c94e71b3b4d7e8be73682d2025-08-20T03:10:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15425261542526Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformationHaiyan Xu0Ying Yang1PingLi Wang2Shengnan Lin3Xiaochun Zhang4Huiwen Ni5Zhiyong Xu6Zhiyong Xu7Department of Biobank, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Biobank, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Biobank, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Biobank, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, ChinaBreast Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, ChinaAdenocarcinoma-to-squamous cell carcinoma transformation (AST) induces drug resistance in patients with lung adenocarcinoma (LUAD), often resulting in unfavorable clinical outcomes. In recent years, it has been found that alterations in the tumor immune microenvironment (TIME) during adenosquamous carcinoma trans-differentiation also influence the efficacy of immunotherapy. Moreover, the aberrant expression and activation of several driver genes for AST lead to abnormal infiltration and function of immune cell by remodeling the cellular inflammatory phenotype. In this review, we will systematically present the changes in the TIME and molecular regulatory mechanisms during adenosquamous carcinoma differentiation, aiming to gain a better understand of the function of immune cells during this process and the potential value of combining immunotherapy to enhance the treatment of non-small cell lung cancer (NSCLC).https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542526/fulladenosquamous lung carcinoma (ASLC)adenocarcinoma-to-squamous cell carcinoma transformation (AST)tumor immune microenvironment (TIME)tumor-associated macrophages (TAMs)tumor-associated neutrophils (TANs) |
| spellingShingle | Haiyan Xu Ying Yang PingLi Wang Shengnan Lin Xiaochun Zhang Huiwen Ni Zhiyong Xu Zhiyong Xu Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation Frontiers in Immunology adenosquamous lung carcinoma (ASLC) adenocarcinoma-to-squamous cell carcinoma transformation (AST) tumor immune microenvironment (TIME) tumor-associated macrophages (TAMs) tumor-associated neutrophils (TANs) |
| title | Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation |
| title_full | Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation |
| title_fullStr | Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation |
| title_full_unstemmed | Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation |
| title_short | Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation |
| title_sort | unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation |
| topic | adenosquamous lung carcinoma (ASLC) adenocarcinoma-to-squamous cell carcinoma transformation (AST) tumor immune microenvironment (TIME) tumor-associated macrophages (TAMs) tumor-associated neutrophils (TANs) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542526/full |
| work_keys_str_mv | AT haiyanxu unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation AT yingyang unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation AT pingliwang unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation AT shengnanlin unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation AT xiaochunzhang unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation AT huiwenni unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation AT zhiyongxu unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation AT zhiyongxu unravelingtheimmunemechanismsandtherapeutictargetsinlungadenosquamoustransformation |